A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
ACTIVE_NOT_RECRUITING
Status
Conditions
- Small-Cell Lung Cancer
- Neuroendocrine Carcinoma
Interventions
- BIOLOGICAL: Gocatamig
- BIOLOGICAL: Atezolizumab
- BIOLOGICAL: Ifinatamab Deruxtecan (I-DXd)
Sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Collaborators